AU2004280256A1 - Pyrovalerone analogs and therapeutic uses thereof - Google Patents
Pyrovalerone analogs and therapeutic uses thereof Download PDFInfo
- Publication number
- AU2004280256A1 AU2004280256A1 AU2004280256A AU2004280256A AU2004280256A1 AU 2004280256 A1 AU2004280256 A1 AU 2004280256A1 AU 2004280256 A AU2004280256 A AU 2004280256A AU 2004280256 A AU2004280256 A AU 2004280256A AU 2004280256 A1 AU2004280256 A1 AU 2004280256A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- mammal
- pentan
- phenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SWUVZKWCOBGPTH-UHFFFAOYSA-N pyrovalerone Chemical class C=1C=C(C)C=CC=1C(=O)C(CCC)N1CCCC1 SWUVZKWCOBGPTH-UHFFFAOYSA-N 0.000 title claims description 16
- 230000001225 therapeutic effect Effects 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims description 265
- 238000000034 method Methods 0.000 claims description 100
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims description 63
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims description 63
- 241000124008 Mammalia Species 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 54
- 229910052801 chlorine Inorganic materials 0.000 claims description 43
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 40
- 230000004064 dysfunction Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 229960003638 dopamine Drugs 0.000 claims description 27
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 claims description 26
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 claims description 26
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims description 22
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- -1 -CF 3 Chemical group 0.000 claims description 17
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 15
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 15
- 230000004770 neurodegeneration Effects 0.000 claims description 15
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 14
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 229950010600 pyrovalerone Drugs 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 229940076279 serotonin Drugs 0.000 claims description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
- 230000002825 dopamine reuptake Effects 0.000 claims description 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
- 230000000697 serotonin reuptake Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010013654 Drug abuse Diseases 0.000 claims description 6
- 201000001272 cocaine abuse Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- XCHIECWEKDGHNL-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(O)C=CC=1C(=O)C(CCC)N1CCCC1 XCHIECWEKDGHNL-UHFFFAOYSA-N 0.000 claims description 5
- 230000000966 norepinephrine reuptake Effects 0.000 claims description 5
- HHSYAWUBPBEDMP-UHFFFAOYSA-N 1-(3-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=CC(C)=CC=1C(=O)C(CCC)N1CCCC1 HHSYAWUBPBEDMP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- KKTUFJIEHNEGDF-UHFFFAOYSA-N 1-(3,4-dihydroxyphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(O)C(O)=CC=1C(=O)C(CCC)N1CCCC1 KKTUFJIEHNEGDF-UHFFFAOYSA-N 0.000 claims description 3
- WXZXQKCLNSPXHL-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-pyrrolidin-1-ylhexan-1-one Chemical compound C=1C=C(OC)C=CC=1C(=O)C(CCCC)N1CCCC1 WXZXQKCLNSPXHL-UHFFFAOYSA-N 0.000 claims description 3
- DLRWKNLMJAIFQB-UHFFFAOYSA-N 1-phenyl-2-pyrrolidin-1-ylheptan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(CCCCC)N1CCCC1 DLRWKNLMJAIFQB-UHFFFAOYSA-N 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- SLPVYNPNJIYANF-UHFFFAOYSA-N 3-methyl-1-phenyl-2-pyrrolidin-1-ylbutan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(C(C)C)N1CCCC1 SLPVYNPNJIYANF-UHFFFAOYSA-N 0.000 claims description 3
- 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- GSESDIFGJCCBHN-UHFFFAOYSA-N α-pyrrolidinobutiophenone Chemical compound C=1C=CC=CC=1C(=O)C(CC)N1CCCC1 GSESDIFGJCCBHN-UHFFFAOYSA-N 0.000 claims description 3
- YDIIDRWHPFMLGR-UHFFFAOYSA-N α-pyrrolidinopentiophenone Chemical compound C=1C=CC=CC=1C(=O)C(CCC)N1CCCC1 YDIIDRWHPFMLGR-UHFFFAOYSA-N 0.000 claims description 3
- SWUVZKWCOBGPTH-HNNXBMFYSA-N (2s)-1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound N1([C@@H](CCC)C(=O)C=2C=CC(C)=CC=2)CCCC1 SWUVZKWCOBGPTH-HNNXBMFYSA-N 0.000 claims description 2
- OVEGFFRUJIZDSI-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-piperidin-1-ylpentan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=O)C(CCC)N1CCCCC1 OVEGFFRUJIZDSI-UHFFFAOYSA-N 0.000 claims description 2
- DZULEPZTNHLZTO-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-pyrrolidin-1-ylbutan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=O)C(CC)N1CCCC1 DZULEPZTNHLZTO-UHFFFAOYSA-N 0.000 claims description 2
- SIFVHGKZPNIKBO-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-pyrrolidin-1-ylpent-4-en-1-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)C(CC=C)N1CCCC1 SIFVHGKZPNIKBO-UHFFFAOYSA-N 0.000 claims description 2
- NIGBFBTVONRYQN-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(Cl)C=CC=1C(=O)C(CCC)N1CCCC1 NIGBFBTVONRYQN-UHFFFAOYSA-N 0.000 claims description 2
- JREHJCKVQXOMFL-UHFFFAOYSA-N 1-(4-methylphenyl)-2-pyrrolidin-1-ylpent-4-en-1-one Chemical compound C1=CC(C)=CC=C1C(=O)C(CC=C)N1CCCC1 JREHJCKVQXOMFL-UHFFFAOYSA-N 0.000 claims description 2
- FDCLNKXJEZCPEW-UHFFFAOYSA-N 1-[4-(hydroxymethyl)phenyl]-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(CO)C=CC=1C(=O)C(CCC)N1CCCC1 FDCLNKXJEZCPEW-UHFFFAOYSA-N 0.000 claims description 2
- SLXSUDJHTGKVGZ-UHFFFAOYSA-N 1-pyrrolidin-1-ylnonan-1-one Chemical compound CCCCCCCCC(=O)N1CCCC1 SLXSUDJHTGKVGZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- RUCXEVOCSDADAL-UHFFFAOYSA-N methyl 4-(2-pyrrolidin-1-ylpentanoyl)benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1C(=O)C(CCC)N1CCCC1 RUCXEVOCSDADAL-UHFFFAOYSA-N 0.000 claims description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- DTNUPBSOODGRKW-UHFFFAOYSA-N naphyrone Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)C(CCC)N1CCCC1 DTNUPBSOODGRKW-UHFFFAOYSA-N 0.000 claims description 2
- 230000001722 neurochemical effect Effects 0.000 claims 2
- SWUVZKWCOBGPTH-OAHLLOKOSA-N (2r)-1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound N1([C@H](CCC)C(=O)C=2C=CC(C)=CC=2)CCCC1 SWUVZKWCOBGPTH-OAHLLOKOSA-N 0.000 claims 1
- VZFAGFYTQOVVOD-UHFFFAOYSA-N IC1=CC=C(C=C1)C(C(CCC)N1CCCC1)=O.CC(CC(C(=O)C1=CC=C(C=C1)C)N1CCCC1)C.C(#CC)C1=CC=C(C=C1)C(C(CCC)N1CCCC1)=O Chemical compound IC1=CC=C(C=C1)C(C(CCC)N1CCCC1)=O.CC(CC(C(=O)C1=CC=C(C=C1)C)N1CCCC1)C.C(#CC)C1=CC=C(C=C1)C(C(CCC)N1CCCC1)=O VZFAGFYTQOVVOD-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- RPOLPKWEADBMRV-UHFFFAOYSA-N N1(CCCC1)C(C(=O)C1=CC=C(C=C1)C=1SC=CC1)CCC.N1(CCCC1)C(C(=O)C1=C(C=CC=C1)C)CCC.N1(CCCC1)C(C(=O)C=1C=C(C=CC1)C)CCC Chemical compound N1(CCCC1)C(C(=O)C1=CC=C(C=C1)C=1SC=CC1)CCC.N1(CCCC1)C(C(=O)C1=C(C=CC=C1)C)CCC.N1(CCCC1)C(C(=O)C=1C=C(C=CC1)C)CCC RPOLPKWEADBMRV-UHFFFAOYSA-N 0.000 claims 1
- YQXBCEZIBQMVRS-CFZZCFLMSA-N N1(CCCC1)[C@H](C(=O)C1=CC=C(C=C1)C)CCC.N1(CCCC1)C(C(=O)C1=CC=C(C=C1)F)CCC.N1(CCCC1)C1=C(C=CC=C1)C(CCCC)=O.N1(CCCC1)C(C(=O)C1=CC(=C(C=C1)Cl)Cl)CCC Chemical compound N1(CCCC1)[C@H](C(=O)C1=CC=C(C=C1)C)CCC.N1(CCCC1)C(C(=O)C1=CC=C(C=C1)F)CCC.N1(CCCC1)C1=C(C=CC=C1)C(CCCC)=O.N1(CCCC1)C(C(=O)C1=CC(=C(C=C1)Cl)Cl)CCC YQXBCEZIBQMVRS-CFZZCFLMSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000019818 neurotransmitter uptake Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 description 81
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 69
- 229910052799 carbon Inorganic materials 0.000 description 44
- 229910052757 nitrogen Inorganic materials 0.000 description 40
- 239000000243 solution Substances 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 37
- 239000003921 oil Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 238000012986 modification Methods 0.000 description 23
- 230000004048 modification Effects 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 238000001953 recrystallisation Methods 0.000 description 12
- 239000012458 free base Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 150000003841 chloride salts Chemical class 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 238000012879 PET imaging Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SAOSCHJZYMDGOB-UHFFFAOYSA-N 2-bromo-1-(4-methylphenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(C)C=C1 SAOSCHJZYMDGOB-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002576 ketones Chemical group 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HWYVHRCKBXGZLV-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(OC)C=CC=1C(=O)C(CCC)N1CCCC1 HWYVHRCKBXGZLV-UHFFFAOYSA-N 0.000 description 3
- KJUXPSRNJJUYTC-UHFFFAOYSA-N 1-(4-methyl-3-pyrrolidin-1-ylphenyl)pentan-1-ol Chemical compound CCCCC(O)C1=CC=C(C)C(N2CCCC2)=C1 KJUXPSRNJJUYTC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BCMBDNBMSRGBHF-UHFFFAOYSA-N 1-(2-methylphenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=CC=C1C BCMBDNBMSRGBHF-UHFFFAOYSA-N 0.000 description 2
- MEMCHWOZQTXCNY-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-(pyrrolidin-1-ylmethyl)pentan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=O)C(CCC)CN1CCCC1 MEMCHWOZQTXCNY-UHFFFAOYSA-N 0.000 description 2
- DQWHNHMUDKNDSE-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=C(OC)C(OC)=C1 DQWHNHMUDKNDSE-UHFFFAOYSA-N 0.000 description 2
- QXBWECFEEZMKTN-UHFFFAOYSA-N 1-(4-iodophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(I)C=CC=1C(=O)C(CCC)N1CCCC1 QXBWECFEEZMKTN-UHFFFAOYSA-N 0.000 description 2
- RYVUHDVTDBWYBX-UHFFFAOYSA-N 1-(4-methylphenyl)pent-2-en-1-one Chemical compound CCC=CC(=O)C1=CC=C(C)C=C1 RYVUHDVTDBWYBX-UHFFFAOYSA-N 0.000 description 2
- HTGLJCRHYKPXNV-UHFFFAOYSA-N 2-(4-methylphenyl)-1-phenyl-3-pyrrolidin-1-ylhexan-2-ol Chemical compound C=1C=CC=CC=1CC(O)(C=1C=CC(C)=CC=1)C(CCC)N1CCCC1 HTGLJCRHYKPXNV-UHFFFAOYSA-N 0.000 description 2
- VNTFCQHGEFDNOJ-UHFFFAOYSA-N 2-bromo-1-(3,4-dichlorophenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(Cl)C(Cl)=C1 VNTFCQHGEFDNOJ-UHFFFAOYSA-N 0.000 description 2
- WACKYVIKLWIXLK-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(C)C=CC=1C(=O)C(C)(CCC)N1CCCC1 WACKYVIKLWIXLK-UHFFFAOYSA-N 0.000 description 2
- AGRVUDWDZKZCAA-UHFFFAOYSA-N 3,4-Dimethoxy-alpha-pyrrolidinopentiophenone Chemical compound C=1C=C(OC)C(OC)=CC=1C(=O)C(CCC)N1CCCC1 AGRVUDWDZKZCAA-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101710178035 Chorismate synthase 2 Proteins 0.000 description 2
- 101710152694 Cysteine synthase 2 Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- DVFXUAIJOKNEMR-UHFFFAOYSA-N n-(4-pentanoylphenyl)acetamide Chemical compound CCCCC(=O)C1=CC=C(NC(C)=O)C=C1 DVFXUAIJOKNEMR-UHFFFAOYSA-N 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000013275 serotonin uptake Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 2
- 229930004006 tropane Natural products 0.000 description 2
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RXTMQWQNMLJUPT-UHFFFAOYSA-N 1-(2-bromo-4,5-dimethoxyphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C(OC)=C(OC)C=C(Br)C=1C(=O)C(CCC)N1CCCC1 RXTMQWQNMLJUPT-UHFFFAOYSA-N 0.000 description 1
- VVIVTDYOMWHKAE-UHFFFAOYSA-N 1-(2-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=CC=C(C)C=1C(=O)C(CCC)N1CCCC1 VVIVTDYOMWHKAE-UHFFFAOYSA-N 0.000 description 1
- OUSCITCGPKFWDH-UHFFFAOYSA-N 1-(2-pyrrolidin-1-ylphenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=CC=C1N1CCCC1 OUSCITCGPKFWDH-UHFFFAOYSA-N 0.000 description 1
- CORXNBZCSJIHLR-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-methyl-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=O)C(C)(CCC)N1CCCC1 CORXNBZCSJIHLR-UHFFFAOYSA-N 0.000 description 1
- OYYFMZJTKZIRQM-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(=O)C(CCC)N1CCCC1 OYYFMZJTKZIRQM-UHFFFAOYSA-N 0.000 description 1
- BQKRARPXRCZXGV-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-pyrrolidin-1-ylpentan-1-one Chemical compound C1CCCN1C(CC)CC(=O)C1=CC=C(Cl)C(Cl)=C1 BQKRARPXRCZXGV-UHFFFAOYSA-N 0.000 description 1
- GLWFMNWVTNHDEO-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)butan-1-one Chemical compound CCCC(=O)C1=CC=C(Cl)C(Cl)=C1 GLWFMNWVTNHDEO-UHFFFAOYSA-N 0.000 description 1
- DAQIQOIKLVJWKH-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=C(Cl)C(Cl)=C1 DAQIQOIKLVJWKH-UHFFFAOYSA-N 0.000 description 1
- NYDUTEZMPZHSRY-UHFFFAOYSA-N 1-(3-iodophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=CC(I)=CC=1C(=O)C(CCC)N1CCCC1 NYDUTEZMPZHSRY-UHFFFAOYSA-N 0.000 description 1
- DAILVTQIKQNYEO-UHFFFAOYSA-N 1-(3-iodophenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=CC(I)=C1 DAILVTQIKQNYEO-UHFFFAOYSA-N 0.000 description 1
- IBUFXWULBFRPGY-UHFFFAOYSA-N 1-(3-methylphenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=CC(C)=C1 IBUFXWULBFRPGY-UHFFFAOYSA-N 0.000 description 1
- RAHKQMUBMIJUFG-UHFFFAOYSA-N 1-(4-bromophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(Br)C=CC=1C(=O)C(CCC)N1CCCC1 RAHKQMUBMIJUFG-UHFFFAOYSA-N 0.000 description 1
- BQLSUBYYRRZHRK-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(F)C=CC=1C(=O)C(CCC)N1CCCC1 BQLSUBYYRRZHRK-UHFFFAOYSA-N 0.000 description 1
- GLMOSAYFENACPD-UHFFFAOYSA-N 1-(4-iodophenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=C(I)C=C1 GLMOSAYFENACPD-UHFFFAOYSA-N 0.000 description 1
- RRFLDGUEDAERPR-UHFFFAOYSA-N 1-(4-methylphenyl)-2-pyrrolidin-1-ylpent-4-yn-1-one Chemical compound C1=CC(C)=CC=C1C(=O)C(CC#C)N1CCCC1 RRFLDGUEDAERPR-UHFFFAOYSA-N 0.000 description 1
- CCCKABNBMAAFTD-UHFFFAOYSA-N 1-(4-methylphenyl)-3-pyrrolidin-1-ylpentan-1-one Chemical compound C1CCCN1C(CC)CC(=O)C1=CC=C(C)C=C1 CCCKABNBMAAFTD-UHFFFAOYSA-N 0.000 description 1
- VNDBXKNCOLJGKH-UHFFFAOYSA-N 1-(4-methylphenyl)pent-4-yn-1-one Chemical compound CC1=CC=C(C(=O)CCC#C)C=C1 VNDBXKNCOLJGKH-UHFFFAOYSA-N 0.000 description 1
- NAHZCGQMXZCULW-UHFFFAOYSA-N 1-(4-nitrophenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=O)C(CCC)N1CCCC1 NAHZCGQMXZCULW-UHFFFAOYSA-N 0.000 description 1
- FCINLQHPPAWABH-UHFFFAOYSA-N 1-(4-prop-1-ynylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(C#CC)C=CC=1C(=O)C(CCC)N1CCCC1 FCINLQHPPAWABH-UHFFFAOYSA-N 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- YCECQFKWCCEISA-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]pentan-1-one Chemical compound CCCCC(=O)C1=CC=C(C(F)(F)F)C=C1 YCECQFKWCCEISA-UHFFFAOYSA-N 0.000 description 1
- STHHLVCQSLRQNI-UHFFFAOYSA-N 1-azabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCC2 STHHLVCQSLRQNI-UHFFFAOYSA-N 0.000 description 1
- SNYBQYXAXAOSOF-UHFFFAOYSA-N 1-naphthalen-2-ylpentan-1-one Chemical compound C1=CC=CC2=CC(C(=O)CCCC)=CC=C21 SNYBQYXAXAOSOF-UHFFFAOYSA-N 0.000 description 1
- RYJXAZXFWIWTOJ-UHFFFAOYSA-N 1-phenyl-2-pyrrolidin-1-ylnonan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(CCCCCCC)N1CCCC1 RYJXAZXFWIWTOJ-UHFFFAOYSA-N 0.000 description 1
- MWRDLBOZBMQUBD-UHFFFAOYSA-N 1-pyrrolidin-1-ylpentan-1-one Chemical compound CCCCC(=O)N1CCCC1 MWRDLBOZBMQUBD-UHFFFAOYSA-N 0.000 description 1
- OCQAXYHNMWVLRH-UHFFFAOYSA-N 2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical class C=1C=CC=CC=1C(=O)C(O)(C(O)=O)C(O)(C(=O)O)C(=O)C1=CC=CC=C1 OCQAXYHNMWVLRH-UHFFFAOYSA-N 0.000 description 1
- HYMIOQDNASQILW-UHFFFAOYSA-N 2-(butylamino)-1-(3,4-dichlorophenyl)pentan-1-one Chemical compound CCCCNC(CCC)C(=O)C1=CC=C(Cl)C(Cl)=C1 HYMIOQDNASQILW-UHFFFAOYSA-N 0.000 description 1
- FLQWDIZNPSYHMH-UHFFFAOYSA-N 2-bromo-1-(2-bromo-4,5-dimethoxyphenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC(OC)=C(OC)C=C1Br FLQWDIZNPSYHMH-UHFFFAOYSA-N 0.000 description 1
- IOSZJLIWNFGYFS-UHFFFAOYSA-N 2-bromo-1-(2-methylphenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=CC=C1C IOSZJLIWNFGYFS-UHFFFAOYSA-N 0.000 description 1
- KZRPLFKVXPXPJR-UHFFFAOYSA-N 2-bromo-1-(3,4-dichlorophenyl)butan-1-one Chemical compound CCC(Br)C(=O)C1=CC=C(Cl)C(Cl)=C1 KZRPLFKVXPXPJR-UHFFFAOYSA-N 0.000 description 1
- YNKKYOKUJBFUTP-UHFFFAOYSA-N 2-bromo-1-(3,4-dimethoxyphenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(OC)C(OC)=C1 YNKKYOKUJBFUTP-UHFFFAOYSA-N 0.000 description 1
- MHGWPBBDPZUNGO-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(Br)C=C1 MHGWPBBDPZUNGO-UHFFFAOYSA-N 0.000 description 1
- VEIXGMMWJKOUMJ-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(F)C=C1 VEIXGMMWJKOUMJ-UHFFFAOYSA-N 0.000 description 1
- AWXVQOZUPHVLMF-UHFFFAOYSA-N 2-bromo-1-(4-iodophenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(I)C=C1 AWXVQOZUPHVLMF-UHFFFAOYSA-N 0.000 description 1
- RTILIJSYRVLPFX-UHFFFAOYSA-N 2-bromo-1-(4-methoxyphenyl)pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(OC)C=C1 RTILIJSYRVLPFX-UHFFFAOYSA-N 0.000 description 1
- AJRUMQHETQGAQL-UHFFFAOYSA-N 2-bromo-1-[4-(hydroxymethyl)phenyl]pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(CO)C=C1 AJRUMQHETQGAQL-UHFFFAOYSA-N 0.000 description 1
- HIOAFDROGTWLBD-UHFFFAOYSA-N 2-bromo-1-[4-(trifluoromethyl)phenyl]pentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=C(C(F)(F)F)C=C1 HIOAFDROGTWLBD-UHFFFAOYSA-N 0.000 description 1
- FFRREEFPTVAIFV-UHFFFAOYSA-N 2-bromo-1-naphthalen-2-ylpentan-1-one Chemical compound C1=CC=CC2=CC(C(=O)C(Br)CCC)=CC=C21 FFRREEFPTVAIFV-UHFFFAOYSA-N 0.000 description 1
- XOQFMNXQYSTQPE-UHFFFAOYSA-N 2-bromo-1-phenylpentan-1-one Chemical compound CCCC(Br)C(=O)C1=CC=CC=C1 XOQFMNXQYSTQPE-UHFFFAOYSA-N 0.000 description 1
- HEFDYDISPNHKAM-UHFFFAOYSA-N 2-pyrrolidin-1-yl-1-(4-thiophen-2-ylphenyl)pentan-1-one Chemical compound C=1C=C(C=2SC=CC=2)C=CC=1C(=O)C(CCC)N1CCCC1 HEFDYDISPNHKAM-UHFFFAOYSA-N 0.000 description 1
- AUSFQRWGUFWXHW-UHFFFAOYSA-N 4-(2-bromopentanoyl)benzonitrile Chemical compound CCCC(Br)C(=O)C1=CC=C(C#N)C=C1 AUSFQRWGUFWXHW-UHFFFAOYSA-N 0.000 description 1
- AQQRGNNYEPRIIF-UHFFFAOYSA-N 4-(2-pyrrolidin-1-ylpentanoyl)benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)C(CCC)N1CCCC1 AQQRGNNYEPRIIF-UHFFFAOYSA-N 0.000 description 1
- GMWFVXBLHOYMAG-UHFFFAOYSA-N 4-methyl-1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one Chemical compound C=1C=C(C)C=CC=1C(=O)C(CC(C)C)N1CCCC1 GMWFVXBLHOYMAG-UHFFFAOYSA-N 0.000 description 1
- PPEFLCWGGLBAGA-UHFFFAOYSA-N 4-methyl-1-(4-methylphenyl)pentan-1-one Chemical compound CC(C)CCC(=O)C1=CC=C(C)C=C1 PPEFLCWGGLBAGA-UHFFFAOYSA-N 0.000 description 1
- NKPHABDFNLMXJW-UHFFFAOYSA-N 5-methylpyrrole Chemical compound CC1=CC=N[CH]1 NKPHABDFNLMXJW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008359 benzonitriles Chemical class 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 108010063333 cocaine receptor Proteins 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 1
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- IATJTXRWQPLRPJ-UHFFFAOYSA-N methyl 4-(2-bromopentanoyl)benzoate Chemical compound CCCC(Br)C(=O)C1=CC=C(C(=O)OC)C=C1 IATJTXRWQPLRPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- DSIUMNNVBQZCEG-UHFFFAOYSA-N n-[4-(2-pyrrolidin-1-ylpentanoyl)phenyl]acetamide Chemical compound C=1C=C(NC(C)=O)C=CC=1C(=O)C(CCC)N1CCCC1 DSIUMNNVBQZCEG-UHFFFAOYSA-N 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003569 transporter assay Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- SANWDQJIWZEKOD-UHFFFAOYSA-N tributyl(furan-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CO1 SANWDQJIWZEKOD-UHFFFAOYSA-N 0.000 description 1
- UKTDFYOZPFNQOQ-UHFFFAOYSA-N tributyl(thiophen-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CS1 UKTDFYOZPFNQOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003813 tropane derivatives Chemical class 0.000 description 1
- XKGLSKVNOSHTAD-UHFFFAOYSA-N valerophenone Chemical compound CCCCC(=O)C1=CC=CC=C1 XKGLSKVNOSHTAD-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50988203P | 2003-10-08 | 2003-10-08 | |
| US60/509,882 | 2003-10-08 | ||
| PCT/US2004/033349 WO2005034878A2 (en) | 2003-10-08 | 2004-10-08 | Pyrovalerone analogs and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004280256A1 true AU2004280256A1 (en) | 2005-04-21 |
Family
ID=34435034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004280256A Abandoned AU2004280256A1 (en) | 2003-10-08 | 2004-10-08 | Pyrovalerone analogs and therapeutic uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080234498A1 (https=) |
| EP (1) | EP1670755A4 (https=) |
| JP (1) | JP2007508314A (https=) |
| AU (1) | AU2004280256A1 (https=) |
| CA (1) | CA2542077A1 (https=) |
| WO (1) | WO2005034878A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US7846945B2 (en) | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| SG10201913554YA (en) | 2011-12-22 | 2020-03-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| BR112015014457A2 (pt) | 2012-12-21 | 2017-11-21 | Alios Biopharma Inc | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c |
| GB2530783A (en) * | 2014-10-02 | 2016-04-06 | Randox Lab Ltd | Improved immunoassay for pyrrolidinophenones |
| MA55556A (fr) | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314970A (en) * | 1967-04-18 | Pykrolidino ketones | ||
| US3287217A (en) * | 1966-11-22 | Compositions and methods for stimulat- ing the central nervous system and in- creasing the blood pressure | ||
| US2369611A (en) * | 1938-12-24 | 1945-02-13 | Scheuing Georg | Analgetically effective tetrahydronaphthalene piperidyl derivatives |
| DE1161274B (de) * | 1960-04-07 | 1964-01-16 | Thomae Gmbh Dr K | Verfahren zur Herstellung von ª‡-Pyrrolidinoketonen und deren Salzen |
| CH395998A (de) * | 1961-05-05 | 1965-07-31 | Wander Ag Dr A | Verfahren zur Herstellung von a-Pyrrolidino-valerophenonen |
| FR2319332A1 (fr) * | 1975-07-28 | 1977-02-25 | Roussel Uclaf | Nouveaux derives de l'aminobenzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments desdits produits |
| HU222726B1 (hu) * | 1990-02-06 | 2003-09-29 | Pfizer, Inc., | Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények |
| JPH051033A (ja) * | 1991-06-18 | 1993-01-08 | Tanabe Seiyaku Co Ltd | ベンゾシクロヘプテン誘導体及びその製法 |
-
2004
- 2004-10-08 EP EP04809902A patent/EP1670755A4/en not_active Withdrawn
- 2004-10-08 CA CA002542077A patent/CA2542077A1/en not_active Abandoned
- 2004-10-08 WO PCT/US2004/033349 patent/WO2005034878A2/en not_active Ceased
- 2004-10-08 AU AU2004280256A patent/AU2004280256A1/en not_active Abandoned
- 2004-10-08 JP JP2006534415A patent/JP2007508314A/ja not_active Withdrawn
- 2004-10-08 US US10/575,177 patent/US20080234498A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007508314A (ja) | 2007-04-05 |
| US20080234498A1 (en) | 2008-09-25 |
| EP1670755A4 (en) | 2007-02-28 |
| WO2005034878A2 (en) | 2005-04-21 |
| EP1670755A2 (en) | 2006-06-21 |
| WO2005034878A3 (en) | 2005-06-30 |
| CA2542077A1 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6051610A (en) | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | |
| CA2168432C (en) | Piperazine compounds used in therapy | |
| KR100366745B1 (ko) | 신경 질환 및 신경 질병의 치료에 유용한 수용체-작동된 칼슘채널의 신규 부위에서 활성인 화합물 | |
| RU2140417C1 (ru) | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения | |
| Vecchietti et al. | (1S)-1-(Aminomethyl)-2-(arylacetyl)-1, 2, 3, 4-tetrahydroisoquinoline and heterocycle-condensed tetrahydropyridine derivatives: members of a novel class of very potent. kappa. opioid analgesics | |
| BRPI0907382B1 (pt) | Antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende | |
| JP2001524954A (ja) | コカインの類似化合物 | |
| AU2008258599A1 (en) | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | |
| BR9808069B1 (pt) | diarilpropilaminas, composição farmacêutica e uso das mesmas, bem como processo para preparação das referidas diarilpropilaminas. | |
| US7101885B2 (en) | Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | |
| HUE032461T2 (en) | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | |
| AU2004280256A1 (en) | Pyrovalerone analogs and therapeutic uses thereof | |
| CN101163669A (zh) | 乙炔衍生物 | |
| JP2008537933A (ja) | トリフルオロメチルベンズアミド誘導体およびその治療上の使用 | |
| AU2003296028A1 (en) | S-substituted N-1-[(hetero)aryl]alkyl-N- [(hetero)aryl] alkylysothiocarbamides, method for the production thereof, physiologically active S-substituted N-1-[(hetero)aryl]alkyl-N-[(hetero)aryl]alkylysothiocarbamides, a pharmaceutical compound and curing method | |
| EP3582783B1 (en) | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
| RU2605931C2 (ru) | Фторзамещенные циклические аминосоединения и способы их получения, фармацевтические композиции и их применения | |
| WO2022041172A1 (zh) | 一种长效低成瘾性化合物在制备药物中的应用 | |
| US7026516B2 (en) | Compounds with high monoamine transporter affinity | |
| JP2010529080A (ja) | 皮質カテコールアミン作動性神経伝達の調節因子としての新規な二置換フェニルピロリジン | |
| RU2289571C2 (ru) | Замещенные производные 5-амино-1-пентен-3-ола, способ их получения и лекарственное средство | |
| JP3162822B2 (ja) | チエノシクロペンタノンオキシムエーテル、製造および組成物 | |
| WO2022041171A1 (zh) | 一种长效低成瘾性化合物及其制备方法 | |
| JPH11507657A (ja) | ドーパミンｄ３レセプタに対する親和性を有する５−アミノアルキル−２−（２−アルコキシフェニル）−ピロール誘導体および精神病の治療におけるその使用 | |
| JP4565747B2 (ja) | テトラヒドロイソキノリンアルカノール誘導体及びそれを含む薬学的組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |